Fig. 6.

rMVA-CD40L/TAA mAb combination is dependent on Fcγ receptors and NK cells. a, b B16.OVA tumor-bearing wild-type and FcγR^−/− mice were grouped according to tumor size. Tumor-bearing littermates either received PBS or were immunized with 5 × 10⁷ TCID₅₀ of rMVA-CD40L (Day 0). Mice received 200 µg of anti-TRP-1 antibody i.p. at days −2, 2, 6, and 10. a Tumor size follow-up (n = 5 mice/group) and b overall survival (n = 10 mice/group). c, d B16.OVA tumor-bearing wild-type and Il15ra^−/− mice were grouped according to tumor size. Tumor-bearing mice either received PBS or were immunized with 5 × 10⁷ TCID₅₀ of rMVA-CD40L (Day 0). Mice received 200 µg of anti-TRP-1 antibody i.p. at days −2, 2, 6, and 10. c Tumor size follow-up (n = 5 mice/group) and d overall survival (n = 10 mice/group). b, d Overall survival of two merged independent experiments. Data in a and c are expressed as mean ± SEM. One-way ANOVA was performed on a and c. Log-rank test on mouse survival was performed for b and d. *p < 0.05; **p < 0.01